Toronto Dominion Bank raised its holdings in Alkermes PLC (NASDAQ:ALKS) by 12.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,875 shares of the company’s stock after buying an additional 212 shares during the period. Toronto Dominion Bank’s holdings in Alkermes PLC were worth $109,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the business. WINTON GROUP Ltd bought a new position in shares of Alkermes PLC in the second quarter valued at $249,000. The Manufacturers Life Insurance Company lifted its stake in shares of Alkermes PLC by 7.6% in the second quarter. The Manufacturers Life Insurance Company now owns 5,804 shares of the company’s stock valued at $336,000 after buying an additional 409 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Alkermes PLC by 13,784.0% in the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock valued at $135,128,000 after buying an additional 2,314,203 shares in the last quarter. Macquarie Group Ltd. lifted its stake in shares of Alkermes PLC by 175.4% in the second quarter. Macquarie Group Ltd. now owns 169,940 shares of the company’s stock valued at $9,851,000 after buying an additional 108,229 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Alkermes PLC by 34.3% in the second quarter. Royal Bank of Canada now owns 40,803 shares of the company’s stock valued at $2,366,000 after buying an additional 10,425 shares in the last quarter. 98.39% of the stock is currently owned by hedge funds and other institutional investors.
In other Alkermes PLC news, CAO Kathryn L. Biberstein sold 13,566 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the transaction, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total transaction of $82,365.00. Following the transaction, the director now owns 9,500 shares in the company, valued at approximately $521,645. The disclosure for this sale can be found here. Insiders have sold a total of 18,066 shares of company stock worth $930,280 in the last 90 days. Company insiders own 5.34% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Toronto Dominion Bank Acquires 212 Shares of Alkermes PLC (ALKS)” was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/10/29/toronto-dominion-bank-acquires-212-shares-of-alkermes-plc-alks.html.
Shares of Alkermes PLC (ALKS) opened at 49.85 on Friday. The company’s market cap is $7.66 billion. The firm has a 50-day moving average of $51.28 and a 200 day moving average of $55.02. Alkermes PLC has a 12 month low of $47.01 and a 12 month high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last posted its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.24%. The business’s revenue for the quarter was up 20.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) EPS. On average, analysts expect that Alkermes PLC will post ($0.04) earnings per share for the current year.
A number of research analysts recently weighed in on the stock. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Barclays PLC set a $50.00 price target on shares of Alkermes PLC and gave the company a “hold” rating in a research report on Thursday. ValuEngine lowered shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Citigroup Inc. set a $62.00 price target on shares of Alkermes PLC and gave the company a “hold” rating in a research report on Thursday. Finally, UBS AG set a $54.00 price target on shares of Alkermes PLC and gave the company a “hold” rating in a research report on Friday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $63.55.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.